TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138
05 avr. 2023 07h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, April 05, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today...
TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock
04 avr. 2023 21h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology CompanyTM committed to more effectively treating cancer using RNA therapeutics, today...
TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock
03 avr. 2023 08h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, April 03, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
TransCode Therapeutics Reports 2022 Results; Provides Business Update
31 mars 2023 16h01 HE
|
TransCode Therapeutics, Inc.
BOSTON, March 31, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial...
TransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138 for Treatment of Pancreatic Cancer
28 févr. 2023 07h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology CompanyTM committed to more effectively treating cancer using RNA therapeutics, announced...
TransCode Therapeutics and BRAIN Biotech join forces to develop a CRISPR-derived technology platform for cancer treatment
22 févr. 2023 08h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced...
TransCode Therapeutics Announces Closing of $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
17 févr. 2023 16h10 HE
|
TransCode Therapeutics, Inc.
BOSTON, Feb. 17, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
TransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
16 févr. 2023 08h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma
31 janv. 2023 16h05 HE
|
TransCode Therapeutics, Inc.
BOSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported...
TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial
29 déc. 2022 08h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Dec. 29, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, announced today...